BioAge Labs
BioAge Labs is a clinical‑stage biopharmaceutical company focused on developing therapeutics for metabolic diseases by targeting the biology of human aging.
Company facts
- Founded
- 2015
- Employees
- 200
- Headquarters
- United States
- CEO
- Kristen Fortney
- Type
- Small Business
About
BioAge Labs is a clinical‑stage biopharmaceutical company focused on developing therapeutics for metabolic diseases by targeting the biology of human aging. Its lead candidate, BGE‑102, is a potent, orally available, brain‑penetrant small‑molecule NLRP3 inhibitor currently in Phase 1 trials for cardiovascular risk and retinal disorders. The company is also advancing long‑acting injectable and oral APJ agonists for obesity, leveraging a proprietary discovery platform built on human longevity data to identify key pathways in metabolic aging. BioAge offers employees the chance to work on cutting‑edge, age‑targeted drug programs within a supportive, inclusive environment. Competitive compensation, comprehensive health and wellness benefits, 401(k) matching, and generous professional‑development resources underscore the company’s commitment to attracting top talent and fostering career growth.